Christoph Klein · 2024
<p class="first" dir="auto" id="d200385e66">A disease is considered rare, when fewer than 1 in 2.000 individuals is affected. Children with rare diseases have traditionally been considered “therapeutic orphans” since the development and commercialization of therapies to treat affected patients rarely promise lucrative financial gains. In view of great progress in molecular and cellular sciences, the emergence of biotechnological tools as well as the rapid development of computer sciences, there is increasing hope for children and their families that previously incurable diseases may in fact be curable in the foreseeable future. Furthermore, disease-overarching perspectives will allow us to re-interpret phenotypes and genotypes. Rare diseases, mostly monogenic conditions, open new avenues of research to understand genes and pathways controlling differentiation, homeostasis and function of cells and organs. While there are historic and ethical reasons to distinguish rare and common diseases, this distinction should not make us believe that rare and common diseases should be fundamentally viewed as separate entities. In fact, translational sciences in rare diseases are critical to define innovative therapeutic principles for patients with common diseases. This thesis will be supported by clinical and scientific data from children with rare diseases of the blood and immune system.
Cited by 0Open access
SBIlab · Zenodo (CERN European Organization for Nuclear Research) · 2024
Source codes for generating results of "A Co-essentiality Network of Cancer Driver Genes Better Prioritizes Anticancer Drugs".
Cited by 0Open access
John Reibetanz · McGill-Queen's University Press eBooks · 2016
Cited by 0
William D. Foster · 2024
Cited by 0
Christos Andronis, Anuj Sharma, Vassilis Virvilis et al. · 2010
Cited by 0
Christos Andronis, Anuj Sharma, Vassilis Virvilis et al. · 2010
Cited by 0
Emiko Desvaux (6109685), Antoine Hamon (11172933), Sandra Hubert (6717833) et al. · Figshare · 2021
Cited by 0Open access
Dominguez-Ramirez, Lenin · Figshare · 2024
Docking, repurposing, ROC, AUC, Gnina, CNN.
Cited by 0Open access
Žužek, Zala, Bolčina, Lara, Kump, Ana et al. · Repository of the University of Ljubljana (University of Ljubljana) · 2024
Cited by 0Open access
Werner Koopman · Socio-Environmental Systems Modeling · 2023
Cited by 0Open access
Gemma Alderton · Science · 2020
Cited by 0
Princeton University Press eBooks · 2025
Cited by 0
Alfred Grech, Mario Farrugia, Michael Balzan · OAR@UM (University of Malta) · 2023
The discovery and development of new drugs is slow, time-consuming and costly. An increasingly attractive option is ‘repurposing’, which is the process of finding new uses for existing drugs. This proposition of repurposing (also called ‘drug repositioning’) has spurred the research community as it has a promising potential to fast track already used drugs into clinical studies for new clinical indications.
Cited by 0Open access
Ravichandran Veerasamy, Raghuraman Seenivasan, Prabha Thangavelu et al. · 2026
Drug repurposing, often called drug repositioning, is a strategic approach that reduces the time, cost, and risk associated with traditional drug development by discovering new therapeutic uses for previously approved or withdrawn drugs. This chapter looks at the history, principles, and possible uses of medication repurposing. Notable accomplishments such as the repurposing of sildenafil and thalidomide demonstrate the efficacy of this approach. Only through phenotypic screening, real-world data analysis, and sophisticated computational techniques can novel drug–disease correlations be discovered. Drugs like dexamethasone and remdesivir were promptly repurposed during the COVID-19 pandemic, demonstrating the need and efficacy of pharmaceutical repurposing. Repurposed medications in oncology, such as aspirin and metformin, demonstrate the wider range of use in different medical specialties. Drug repurposing tactics seem to benefit from the integration of artificial intelligence, machine learning, and collaborative efforts, despite obstacles such as regulatory hurdles, potential negative effects, and intellectual property issues. Another important factor in quickening the evaluation process is the use of creative clinical trial designs, such as adaptive trials. All things considered, medication repurposing provides a practical and effective means of meeting unmet medical requirements, enhancing patient outcomes, and making the most use of healthcare resources.
Cited by 0
Elizabeth R. Sharlow · Assay and Drug Development Technologies · 2016
Drug repurposing can be a cost-effective strategy to identify new small molecule-based therapies. Thus, drug repurposing significantly influences the discovery of therapeutics, particularly for rare and neglected diseases, which are often constrained by limited research and development funds. The push for translational science and access to drug discovery-associated resources such as high throughput screening instrumentation, assay development expertise, and Food and Drug Administration-approved drug libraries have intensified interest in drug repurposing. However, successful drug repurposing is highly challenging and subject to particular limitations. Despite these challenges, drug repurposing is a critical component to any comprehensive drug discovery strategy and has the capacity to benefit a wide variety of therapeutically underserved diseases.
Cited by 18
Gaurav Singh · IEEE Multimedia · 2004
This special issue focuses on the challenges, architectures, technology, and tools for content repurposing.Typically, Web content comprises text, images, animations, and video. Since images,animations, and video are harder to handle, the early content repurposing efforts focused on delivering text. While this is useful for many applications such as stock quotes, weather conditions,traffic updates, and news headlines, users are accustomed to the Web experience and want to receive richer content. In many situations, such as when users are mobile or short of time, they find it easier to comprehend information presented as images and videos. The articles in this special issue focus on rich content only.
Cited by 22
Santos, Margarida Pinheiro dos · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 2017
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2015
Cited by 0
Sarfaraz K. Niazi · 2024
Cited by 0
Whitacre, Ryan · OSF Preprints (OSF Preprints) · 2023
This data set examines the practice of repurposing drugs for multiple therapeutic purposes, which is a persistent 'innovation' strategy in the pharmaceutical industry.
Cited by 0Open access
University of Wisconsin Digital Collections (University of Wisconsin) · 1950
Cited by 0